RRAS2 and lymphoma: Our future works will also be oriented to study if SNP rs8570 can also be of value as a predictive/prognostic marker in other malignancies where RRAS2 has been described to be involved, such as breast cancer [24] (Cifuentes et al., submitted), oral cancers [17], esophageal tumors [18] and lymphomas [12], as well as in other cancers in which the role of RRAS2 overexpression is yet to be studied.